$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000148381313000051 Filed on May 08, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q4
Revenue	$14.45M	$11.83M	$21.79M
YoY Change	86.33%	59.04%	803.86%
Cost Of Revenue	$1.284M	$739.0K	$700.0K
YoY Change	797.15%	944.36%	600.0%
Gross Profit	$1.816M	$769.0K	$805.9K
YoY Change	375.61%	559.24%	-66.42%
Gross Profit Margin	12.56%	6.5%	3.7%
Selling, General & Admin	$7.300M	$7.556M	$7.000M
YoY Change	30.81%	14.16%	18.64%
% of Gross Profit	401.98%	982.57%	868.65%
Research & Development	$27.99M	$22.03M	$18.60M
YoY Change	74.05%	38.66%	24.83%
% of Gross Profit	1541.35%	2865.28%	2308.12%
Depreciation & Amortization	$300.0K	$295.0K	$300.0K
YoY Change	0.0%	24.06%	50.0%
% of Gross Profit	16.52%	38.36%	37.23%
Operating Expenses	$35.29M	$29.59M	$25.50M
YoY Change	62.92%	31.45%	23.19%
Operating Profit	-$22.12M	-$18.50M	-$24.69M
YoY Change	57.47%	22.16%	34.94%
Interest Expense	$849.0K	$848.0K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$58.00K	$55.00K
YoY Change	114.98%	159.23%
Pretax Income	-$22.90M	-$19.30M	-$4.400M
YoY Change	63.57%	27.81%	-76.09%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$22.91M	-$19.29M	-$4.406M
YoY Change	63.41%	27.58%	-76.08%
Net Earnings / Revenue	-158.52%	-163.01%	-20.22%
Basic Earnings Per Share
Diluted Earnings Per Share	-$203.6K	-$171.7K	-$39.15K
COMMON SHARES
Basic Shares Outstanding	113.2M shares	113.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.00M	$87.43M	$99.50M
YoY Change	-25.49%	-25.02%	88.45%
Cash & Equivalents	$27.93M	$39.02M	$99.50M
Short-Term Investments	$48.10M	$48.41M	$0.00
Other Short-Term Assets	$11.10M	$10.60M	$12.80M
YoY Change	8.82%	19.1%	54.22%
Inventory	$2.467M	$2.737M	$2.671M
Prepaid Expenses
Receivables	$10.83M	$10.38M	$15.70M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$100.4M	$111.1M	$130.6M
YoY Change	-16.11%	-16.21%	104.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.577M	$3.975M	$3.700M
YoY Change	128.83%	80.68%	108.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.400M	$1.800M	$400.0K
YoY Change
Total Long-Term Assets	$6.966M	$5.756M	$4.100M
YoY Change	248.32%	174.09%	131.53%
TOTAL ASSETS
Total Short-Term Assets	$100.4M	$111.1M	$130.6M
Total Long-Term Assets	$6.966M	$5.756M	$4.100M
Total Assets	$107.4M	$116.9M	$134.7M
YoY Change	-11.76%	-13.24%	104.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.481M	$2.885M	$2.272M
YoY Change	256.24%	-3.84%	-69.94%
Accrued Expenses	$15.29M	$9.178M	$7.783M
YoY Change	103.86%	27.47%	38.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.643M	$1.362M	$0.00
YoY Change
Total Short-Term Liabilities	$32.83M	$19.75M	$18.95M
YoY Change	103.93%	18.27%	9.5%
LONG-TERM LIABILITIES
Long-Term Debt	$28.20M	$29.80M	$29.66M
YoY Change
Other Long-Term Liabilities	$678.7K	$436.8K	$0.00
YoY Change	-98.14%	-98.82%	-100.0%
Total Long-Term Liabilities	$678.7K	$436.8K	$29.66M
YoY Change	-98.14%	-98.82%	-21.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.83M	$19.75M	$18.95M
Total Long-Term Liabilities	$678.7K	$436.8K	$29.66M
Total Liabilities	$33.51M	$20.19M	$48.61M
YoY Change	-36.17%	-62.41%	-11.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$340.8M	-$317.9M	-$298.6M
YoY Change			21.86%
Common Stock	$352.0M	$349.6M	$347.4M
YoY Change			35.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.14M	$31.68M	$48.86M
YoY Change
Total Liabilities & Shareholders Equity	$107.4M	$116.9M	$134.7M
YoY Change	-11.76%	-13.24%	104.88%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q4
OPERATING ACTIVITIES
Net Income	-$22.91M	-$19.29M	-$4.406M
YoY Change	63.41%	27.58%	-76.08%
Depreciation, Depletion And Amortization	$300.0K	$295.0K	$300.0K
YoY Change	0.0%	24.06%	50.0%
Cash From Operating Activities	-$10.90M	-$10.75M	-$16.90M
YoY Change	-20.44%	-44.47%	25.19%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	$534.0K	-$500.0K
YoY Change	-85.71%		0.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$48.90M
YoY Change
Cash From Investing Activities	-$100.0K	-$49.48M	-$500.0K
YoY Change	-85.71%	-312401.19%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-$252.0K	29.70M
YoY Change	-100.0%	-100.3%	4850.0%
NET CHANGE
Cash From Operating Activities	-10.90M	-$10.75M	-16.90M
Cash From Investing Activities	-100.0K	-$49.48M	-500.0K
Cash From Financing Activities	0.000	-$252.0K	29.70M
Net Change In Cash	-11.00M	-$60.48M	12.30M
YoY Change	-24.14%	-194.83%	-191.79%
FREE CASH FLOW
Cash From Operating Activities	-$10.90M	-$10.75M	-$16.90M
Capital Expenditures	-$100.0K	$534.0K	-$500.0K
Free Cash Flow	-$10.80M	-$11.28M	-$16.40M
YoY Change	-16.92%	-41.71%	26.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2271689	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2884794	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15703087	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10375733	USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9177574	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7783447	USD
CY2012Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2223242	USD
CY2013Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	5484727	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6680627	USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6740909	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29131	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	347314658	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	349459065	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2154928	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2396687	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	181916	USD
CY2012Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9100000	shares
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7500000	shares
CY2013Q1	us-gaap	Assets Assets	116866295	USD
CY2012Q4	us-gaap	Assets Assets	134728397	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	111110478	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	130627935	USD
CY2012Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	98024269	USD
CY2013Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	84052145	USD
CY2013Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	48437351	USD
CY2013Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2013Q1	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	48408220	USD
CY2013Q1	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	30646	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1515	USD
CY2012Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	628535	USD
CY2013Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	35157	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1450000	USD
CY2013Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1450000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99501264	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39017804	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116608304	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52825527	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-60483460	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	63782777	USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112709174	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	113142900	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	113142900	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112709174	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	112709	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	113143	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15119181	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19317500	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	738971	USD
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	70761	USD
CY2012Q1	us-gaap	Costs And Expenses CostsAndExpenses	22580577	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	30329313	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	861879	USD
CY2013Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	906091	USD
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	43845983	USD
CY2013Q1	us-gaap	Deferred Revenue DeferredRevenue	40644639	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8891017	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6326158	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	34954966	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	34318481	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	295000	USD
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	238000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	237793	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	294664	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2418495	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4053590	USD
CY2013Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6988	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1980892	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3609171	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5327354	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3288365	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	49129	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	42940	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3201344	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1731577	USD
CY2012Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	929520	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	66691	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1210965	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	577817	USD
CY2012Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-100000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	847584	USD
CY2013Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	848000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	396938	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	751378	USD
CY2013Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1025062	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	2670696	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	2737387	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-251846	USD
CY2013Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1040677	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1127061	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	792257	USD
CY2013Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	671648	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134728397	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116866295	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19750581	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18946153	USD
CY2013Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	10324946	USD
CY2012Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	7252768	USD
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	29661680	USD
CY2013Q1	us-gaap	Long Term Debt LongTermDebt	28323233	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2013Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1362055	USD
CY2012Q4	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2013Q1	us-gaap	Marketable Securities MarketableSecurities	48408220	USD
CY2013Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a science-driven, biopharmaceutical company committed to making molecules into medicines for patients in need. Our research focuses primarily on human enzymes that alter the extracellular matrix. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, thus enhancing the efficacy and the convenience of other drugs or to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, such as diabetes, oncology and dermatology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the product candidates in our current pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. Our proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. We currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Pfizer Inc. (“Pfizer”), Baxter Healthcare Corporation (“Baxter”), ViroPharma Incorporated (“ViroPharma”), and Intrexon Corporation (“Intrexon”), with three product candidates which have been submitted for regulatory approval in the U.S. and/or Europe as well as several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were founded in 1998 and reincorporated from the State of Nevada to the State of Delaware in November 2007. Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these Notes to Condensed Consolidated Financial Statements refers to Halozyme Therapeutics, Inc. and our wholly-owned subsidiary, Halozyme, Inc.</font></div></div>
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10571334	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1280765	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	0	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83124548	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49480712	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15844	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10750902	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19357615	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-19288369	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-15119181	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15140398	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18495773	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1506615	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1274352	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	437000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-29131	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	436849	USD
CY2012Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2013Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	470084	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	54988	USD
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21217	USD
CY2013Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	309123	USD
CY2012Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2013Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48946615	USD
CY2012Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	534097	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12752888	USD
CY2013Q1	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	400000	USD
CY2013Q1	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81476845	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81500000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	57277	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1647703	USD
CY2012Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15844	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10715961	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10381089	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3700462	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3975052	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22034437	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15891109	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298573648	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-317862017	USD
CY2012Q1	us-gaap	Revenues Revenues	7440179	USD
CY2013Q1	us-gaap	Revenues Revenues	11833540	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1508594	USD
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	187411	USD
CY2012Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6618707	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7555905	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2396687	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2154928	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7100000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8500000	shares
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7820000	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	48853719	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	31681060	USD
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	107589514	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112416792	shares
CY2013Q1	halo	Additional Achievement Of Development And Regulatory Milestones AdditionalAchievementOfDevelopmentAndRegulatoryMilestones	84000000	USD
CY2013Q1	halo	Additional Maximum Proceeds Receivable From Partner Of License And Collaborative Agreement Upon Achievement Of Clinical Development Milestones AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones	58500000	USD
CY2012Q1	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.02
CY2013Q1	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.02
CY2013Q1	halo	Available For Sale Maturities Debt Maturities Next Twelve To Eighteen Months Fair Value AvailableForSaleMaturitiesDebtMaturitiesNextTwelveToEighteenMonthsFairValue	22500000	USD
CY2013Q1	halo	Available For Sale Securities Sold AvailableForSaleSecuritiesSold	0	USD
CY2013Q1	halo	Debt Instrument Final Payment DebtInstrumentFinalPayment	2550000.00	USD
CY2012Q1	halo	Public Offering Price Per Share PublicOfferingPricePerShare	10.61
CY2012Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1020000	shares
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	113160891	shares
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC

Files In Submission

Name	View Source	Status
0001483813-13-000051-index-headers.html	Edgar Link	pending
0001483813-13-000051-index.html	Edgar Link	pending
0001483813-13-000051.txt	Edgar Link	pending
0001483813-13-000051-xbrl.zip	Edgar Link	pending
ex101leasemodification.htm	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
halo-20130331.xml	Edgar Link	completed
halo-20130331.xsd	Edgar Link	pending
halo-20130331_cal.xml	Edgar Link	unprocessable
halo-20130331_def.xml	Edgar Link	unprocessable
halo-20130331_lab.xml	Edgar Link	unprocessable
halo-20130331_pre.xml	Edgar Link	unprocessable
halo1q2013x10q.htm	Edgar Link	pending
pipeline.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2013 Q2 Form 10-Q Financial Statement

#000148381313000051 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2013 Q2 Form 10-Q Financial Statement

#000148381313000051 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo